AdHER2DC vaccine + PATHWAY HER2 (4B5) assay + PEMBROLIZUMAB + LENVATINIB for endometrial neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 12 Feb 2024: Trial registered, NCT06253494
  2. 14 May 2024: Trial started, NCT06253494

The trials

NCT06253494: Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

State
Under way
Phase
Phase 1 and Phase 2
People
60 planned
Started
14 May 2024
Primary completion
31 Dec 2026
Arms
Arm 1
Results
None posted
  1. 12 Feb 2024: Trial registered
  2. 14 May 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.